3 results about "Herpesviridae" patented technology

The invention belongs to the field of medicines, and particularly discloses application of a perfoliote knotweed herb water extract in preventing and treating herpes virus and poxvirus infection. The extraction method of the perfoliote knotweed herb water extract comprises the following steps: S1, picking a perfoliote knotweed herb fresh product, cutting into sections, and crushing with a crusher; s2, performing ultrasonic extraction with deionized water at the normal temperature of 20-45 DEG C; s3, filtering with filter cloth to obtain a perfoliote knotweed herb water extract; and S4, standing the perfoliote knotweed herb water extract for 12-24 hours, and centrifuging to obtain water extract supernate. The perfoliote knotweed herb water extract obtained by the invention has inhibitory activity on poxviridae orthopoxvirus vaccinia virus infection, and can be used for treating pox, monkey pox and the like; the compound has inhibitory activity on herpes simplex virus type 1 and varicella-zoster virus infection of herpes viridae, and can be used for treating herpes simplex virus infection of oral cavity, periorbital and pudendum skin or mucosa and treating varicella and zoster. The method has application value in practice.

The present invention generally provides for a novel NEC-targeted strategy for the development of antiherpesviral drugs as well as for a novel antiviral strategy targeting the viral-cellular nuclear egress complex (NEC) for a small molecule-based therapy or prophylaxis to control infections with human cytomegalovirus or other pathogenic viruses of the group of the Herpesviridae. Methods for screening agents / compounds / small molecules modulating / inhibiting the nuclear egress complex of Herpesviridae are provided as well. Specifically novel drug targets of the viral nuclear egress complex of viruses of the Herpesviridae are provided.

An engineered enucleated mesenchymal stem cell (EMC) and its preparation method and application are disclosed, which can effectively solve the problem of preparing engineered enucleated EMC and realize its application in the preparation of drugs for treating herpesvirus infections. The steps are as follows: Lentiviral transfection is used to obtain EMC overexpressing Nectin-1, the overexpression being achieved through genetic engineering, including transfection of EMC using a lentiviral vector or adenovirus vector; then, enucleation is performed using discontinuous density gradient centrifugation to obtain the engineered enucleated EMC. The engineered enucleated EMC of this invention acts as "bait" to competitively capture viruses; the enucleation design fundamentally eliminates the risk of viral replication and leakage within cells; and the captured viruses are subsequently cleared along with the engineered enucleated EMC's own programmed apoptosis and subsequent macrophage phagocytosis, thereby achieving safe and efficient virus capture and physical clearance.